Sponsored by Hudson Rock – Use Hudson Rock's free cybercrime intelligence tools to learn how Infostealer infections are impacting your business
Group: Sarcoma
Discovered by ransomware.live: 2025-04-05
Estimated attack date: 2025-04-05
Description:
Fujifilm has actively promoted the research and development of liposome formulations by harnessing its advanced nano-dispersion technology, analysis technology, and process technology cultivated and evolved through its wide range of product development. In 2017, the company began a U.S. Phase I clinical trial of FF-10832, a liposome-based agent that encapsulates the approved anti-cancer agent gemcitabine *** . In the preclinical mice studies on FF-10850 and FF-10832 *4 Fujifilm has observed the extension of the survival period as a result of immune checkpoint inhibitor *5 combination therapy. In addition, Fujifilm has been promoting the application of liposome for use with next-generation drugs such as nucleic acid drugs and gene therapy drugs. Looking towards future growth, in order to ensure a stable supply of high-quality liposome formulations, Fujifilm is developing a manufacturing facility for producing investigational and commercial drugs through its subsidiary, FUJIFILM Toyama.Geo: Singapore - Leak size: NO DATA 1 pdf - Contains: NO DATA 1 pdf
Compromised Employees: 29
Compromised Users: 680
Third Party Employee Credentials: 143
External Attack Surface: 112
DNS Records:
The following DNS records were found for the victim's domain.
Legal Disclaimer: Ransomware.live does not engage in the acquisition, exfiltration, downloading, possession, hosting, access, consultation, redistribution, or disclosure of unlawfully obtained data. This platform indexes only publicly visible information posted by ransomware operators and open web sources without accessing or obtaining the underlying stolen content. The service is provided to support public awareness, legitimate research, and cyber-resilience. No stolen personal or confidential data is collected or distributed via this site.